Screener
Royalty Pharma RPRX Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Royalty Pharma in its filing.
Tagged under the XBRL concept us-gaap:InterestExpenseNonoperating.
The source filing: Royalty Pharma’s 10-Q, filed August 5, 2026. Open the filing →
- Filed
- Aug 5, 2026, 9:02 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001802768-26-000015
FAQ
- What is Royalty Pharma's interest expense?
- Royalty Pharma (RPRX) reported interest expense of $93.62M in Q2 2026.
- How has Royalty Pharma's interest expense changed year-over-year?
- Royalty Pharma's interest expense increased by 36.3% year-over-year, from $68.67M to $93.62M.
- What is the long-term trend for Royalty Pharma's interest expense?
- Over 4 years (2021 to 2025), Royalty Pharma's interest expense has grown at a 16.7% compound annual growth rate (CAGR), from $166.14M to $307.66M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.
Ask your AI about Royalty Pharma's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude